Your browser doesn't support javascript.
loading
IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells.
Kehl, Niklas; Kilian, Michael; Michel, Julius; Wagner, Tim R; Uhrig, Sebastian; Brobeil, Alexander; Sester, Lilli-Sophie; Blobner, Sven; Steiger, Simon; Hundemer, Michael; Weinhold, Niels; Rippe, Karsten; Fröhling, Stefan; Eichmüller, Stefan B; Bunse, Lukas; Müller-Tidow, Carsten; Goldschmidt, Hartmut; Platten, Michael; Raab, Marc-Steffen; Friedrich, Mirco J.
Afiliación
  • Kehl N; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Kilian M; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Michel J; Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Wagner TR; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Uhrig S; Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Brobeil A; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Sester LS; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Blobner S; Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Steiger S; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Hundemer M; GMP and Cell Therapy Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Weinhold N; Molecular Precision Oncology Program, National Center for Tumor Diseases, Heidelberg, Germany.
  • Rippe K; Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Fröhling S; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Eichmüller SB; Department of Translational Oncology, National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Bunse L; Division of Chromatin Networks, BioQuant Center and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Müller-Tidow C; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Goldschmidt H; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Platten M; Division of Chromatin Networks, BioQuant Center and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Raab MS; Department of Translational Oncology, National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Friedrich MJ; GMP and Cell Therapy Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
J Immunother Cancer ; 10(10)2022 10.
Article en En | MEDLINE | ID: mdl-36252999
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido